Inside Precision Medicine January 26, 2024
Cambridge-based Sano Genetics has raised $11.4M in a new funding round to drive its clinical trials software platform in precision medicine.
The latest funding was led by early-stage investors Plural with the participation of venture capitalists MMC Ventures, which led its Series A round, as well as existing contributors Episode 1 and Seedcamp. It brings the total raised to $22M.
Sano’s 360° platform uses AI to streamline the trial process, combining genetic testing, recruitment, long-term patient engagement and analytics.
This allows pharma and biotech companies to find, screen and speed patient enrollment into studies of precision medicines.
The platform has supported around 20 studies, including rare diseases affecting newborns and neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) and Parkinson’s.
...Today's Sponsors
Today's Sponsor